The effect of adjuvant chemotherapy on plasma TAT and F 1+2 levels in patients with breast cancer
BIOMEDICINE & PHARMACOTHERAPY, cilt.73, ss.19-23, 2015 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 73
- Basım Tarihi: 2015
- Doi Numarası: 10.1016/j.biopha.2015.05.003
- Dergi Adı: BIOMEDICINE & PHARMACOTHERAPY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.19-23
- Anahtar Kelimeler: Thrombin-antithrombin, Prothrombin fragment 1+2, Breast cancer, VENOUS THROMBOEMBOLISM, D-DIMER, VIENNA CANCER, PROTHROMBOTIC STATE, LUNG-CANCER, RISK, COAGULATION, ACTIVATION, PROTEIN, MARKER
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Introduction: Increased thromboembolic disorders and chemotherapy-induced thromboembolic events are well known phenomena in patients with breast cancer. Antithrombin III (AT III) inactivates thrombin, resulting in increased thrombin-antithrombin (TAT) levels. Activated factor X cleaves prothrombin and thrombin, resulting in increased levels of prothrombin fragment 1 + 2 (F 1 + 2). Increased TAT and F 1 + 2 levels show coagulation activation. The aim of this study was to examine plasma levels of TAT and F 1 + 2 and the effect of anthracycline-based chemotherapy on plasma TAT and F 1 + 2 in patients with operable breast cancer.